Nasdaq · CIK 0000933974
AZTA Azenta, Inc.
Insider trading from SEC Form 4. Last filing 19 d ago. Close $37.72 on Oct 9, 2026, +135% from the 52-week low and -12% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
21
with a Form 4 at this company
Price and insider trades, last year
AZTAOct 9, 2026 · close 37.72
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Azenta, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 25Weak | John Marotta President and CEO sell | $9,294 316 shares | -0% | +17% from low-47% from high | |
| 41Moderate | Lawrence Y. Lin EVP, CFO and Treasurer buy | $70k 2,500 shares | +6% | +12% from low-49% from high | |
| 15Weak | Ginger Zhou SVP and General Manager, Genom buy | $19k 417 shares | +2% | - | |
| 15Weak | Violetta Hughes VP, Chief Accounting Officer sell | $17k 317 shares | -3% | - | |
| 42Moderate | Herman Cueto EVP, Chief Financial Officer sell | $29k 712 shares | -3% | - | |
| 36Weak | Jason Joseph SVP, General Counsel, Secy. sell | $46k 1,139 shares | -1% | - | |
| 30Weak | David Dong Wang SVP & GM, SMS sell | $14k 348 shares | -1% | - | |
| 30Weak | Ginger Zhou SVP and General Manager, Genom sell | $20k 491 shares | -2% | - | |
| 30Weak | Violetta Hughes VP, Chief Accounting Officer sell | $6,531 163 shares | -2% | - | |
| 30Weak | Olga Pirogova SVP and CHRO sell | $22k 548 shares | -3% | - | |
| 52Moderate | Martin D Madaus Interim CEO buy | $201k 4,940 shares | +200% | - | |
| 58Moderate | William L Cornog director buy | $495k 12,500 shares | +554% | - | |
| 42Moderate | Didier Hirsch director buy | $40k 1,000 shares | +41% | - | |
| 62Notable | John Marotta President and CEO buy | $553k 13,967 shares | +16% | - | |
| 30Weak | Herman Cueto EVP, Chief Financial Officer sell | $70k 1,595 shares | -6% | - |
Congressional trades
4 trades in AZTA disclosed by members of Congress under the STOCK Act. All congressional trades.
- Gilbert Ray Cisneros, Jr.House · D-CA · last Apr 7, 20263 bought
0 sold - Josh GottheimerHouse · D-NJ · last Apr 10, 20250 bought
1 sold
| Member | Trade | Asset | Reported range | Trade / filing date | Source |
|---|---|---|---|---|---|
Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | AZTA Azenta, Inc. - Common Stock | $1,001 to $15k | Mar 3 / Apr 7 35 days after the trade | Clerk |
Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | AZTA Azenta, Inc. - Common Stock | $1,001 to $15k | Jan 15 / Feb 13 29 days after the trade | Clerk |
Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | AZTA Azenta, Inc. - Common Stock | $1,001 to $15k | Oct 9, 2025 / Nov 18, 2025 40 days after the trade | Clerk |
Josh Gottheimer House · D-NJ | Sale | AZTA Azenta, Inc. - Common Stock | $1,001 to $15k | Mar 19, 2025 / Apr 10, 2025 22 days after the trade | Clerk |
Transactions
The last 59 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 22, 2026 | Martin D Madaus Interim CEO | FTax withholding Common | -1,456 | $34.28 | $50k | 42,602 | 19 d ago |
| Sep 15, 2026 | Erik J. Bello VP Chief Accounting Officer | AGrant or award Common | +4,586 | $0.00 | $0 | 4,586 | 26 d ago |
| Sep 14, 2026 | Martin D Madaus Interim CEO | AGrant or award Common | +36,653 | $0.00 | $0 | 44,058 | 26 d ago |
| Sep 14, 2026 | William E. Martin III President Multiomics | AGrant or award Common | +15,272 | $0.00 | $0 | 33,062 | 26 d ago |
| Sep 14, 2026 | Lawrence Y. Lin EVP, CFO and Treasurer | AGrant or award Common | +30,544 | $0.00 | $0 | 110,199 | 26 d ago |
| Sep 14, 2026 | Ephraim Starr SVP, Gen Counsel & Secretary | AGrant or award Common | +15,272 | $0.00 | $0 | 84,000 | 26 d ago |
| Sep 14, 2026 | Olga Pirogova SVP and CHRO | AGrant or award Common | +15,272 | $0.00 | $0 | 47,225 | 26 d ago |
| Sep 10, 2025 | John Marotta President and CEO | SOpen-market sale Common | -316 | $29.41 | $9,294 | 105,980 | Sep 12, 2025 |
| Aug 12, 2025 | Olga Pirogova SVP and CHRO | DDisposition to issuer Common | -1,085 | $28.54 | $31k | 18,288 | Aug 13, 2025 |
| Aug 12, 2025 | Ginger Zhou SVP and GM, Multiomics | DDisposition to issuer Common | -1,085 | $28.54 | $31k | 26,831 | Aug 13, 2025 |
| Aug 11, 2025 | Lawrence Y. Lin EVP, CFO and Treasurer | POpen-market purchase Common | +2,500 | $27.96 | $70k | 46,013 | Aug 12, 2025 |
| Jun 2, 2025 | John Marotta President and CEO | AGrant or award Common | +1,000 | $25.99 | $26k | 107,296 | Jun 4, 2025 |
| May 8, 2025 | John Marotta President and CEO | AGrant or award Common | +3,638 | $27.49 | $100k | 104,500 | Jun 4, 2025 |
| May 9, 2025 | John Marotta President and CEO | AGrant or award Common | +1,796 | $27.49 | $49k | 106,296 | Jun 4, 2025 |
| May 30, 2025 | Alan J Malus director | AGrant or award Common | +12,000 | $26.65 | $320k | 17,035 | Jun 3, 2025 |
| May 15, 2025 | Ephraim Starr SVP, Gen Counsel & Secretary | AGrant or award Common | +37,779 | $26.71 | $1.0M | 37,779 | May 27, 2025 |
| May 16, 2025 | William L Cornog director | AGrant or award Commonindirect: See footnote | +100 | $26.50 | $2,650 | 14,855 | May 20, 2025 |
| May 19, 2025 | William L Cornog director | AGrant or award Commonindirect: See footnote | +4,152 | $26.98 | $112k | 19,007 | May 20, 2025 |
| May 20, 2025 | William L Cornog director | AGrant or award Commonindirect: See footnote | +2,748 | $27.37 | $75k | 21,755 | May 20, 2025 |
| May 8, 2025 | John Marotta President and CEO | AGrant or award Common | +3,638 | $27.49 | $100k | 102,658 | May 12, 2025 |
| May 8, 2025 | Lawrence Y. Lin EVP, CFO and Treasurer | AGrant or award Common | +2,000 | $27.67 | $55k | 39,513 | May 12, 2025 |
| May 9, 2025 | John Marotta President and CEO | AGrant or award Common | +1,796 | $27.84 | $50k | 106,296 | May 12, 2025 |
| May 9, 2025 | Lawrence Y. Lin EVP, CFO and Treasurer | AGrant or award Common | +4,000 | $27.49 | $110k | 43,513 | May 12, 2025 |
| Feb 11, 2025 | Lawrence Y. Lin EVP, CFO and Treasurer | AGrant or award Common | +2,200 | $46.00 | $101k | 37,513 | Feb 13, 2025 |
| Feb 7, 2025 | Quentin Koffey director | AGrant or award Common Stock | +4,040 | $0.00 | $0 | 5,035 | Feb 11, 2025 |
| Feb 7, 2025 | Martin D Madaus Interim CEO | AGrant or award Restricted Stock Unitderivative | +4,040 | - | - | 4,040 | Feb 11, 2025 |
| Feb 7, 2025 | William L Cornog director | AGrant or award Restricted Stock Unitderivative | +4,040 | - | - | 4,040 | Feb 11, 2025 |
| Feb 7, 2025 | Alan J Malus director | AGrant or award Common | +4,040 | $52.32 | $211k | 5,035 | Feb 11, 2025 |
| Feb 7, 2025 | Robyn C Davis director | AGrant or award Common | +4,040 | $52.32 | $211k | 33,627 | Feb 11, 2025 |
| Feb 7, 2025 | Tina Susan Nova director | AGrant or award Common | +4,040 | $52.32 | $211k | 10,109 | Feb 11, 2025 |
| Feb 7, 2025 | Dipal Doshi director | AGrant or award Common | +4,040 | $52.32 | $211k | 4,040 | Feb 11, 2025 |
| Feb 7, 2025 | Erica McLaughlin director | AGrant or award Common | +4,040 | $52.32 | $211k | 16,858 | Feb 11, 2025 |
| Feb 7, 2025 | Frank Casal director | AGrant or award Common | +5,168 | $52.32 | $270k | 14,560 | Feb 11, 2025 |
| Feb 3, 2025 | Violetta Hughes VP, Chief Accounting Officer | SOpen-market sale Common | -317 | $52.97 | $17k | 9,603 | Feb 4, 2025 |
| Jan 31, 2025 | Ginger Zhou SVP and General Manager, Genom | POpen-market purchase Common | +417 | $45.88 | $19k | 27,916 | Feb 4, 2025 |
| Dec 5, 2024 | Lawrence Y. Lin EVP, CFO and Treasurer | AGrant or award Common | +23,045 | $45.00 | $1.0M | 29,545 | Dec 9, 2024 |
| Dec 5, 2024 | Lawrence Y. Lin EVP, CFO and Treasurer | AGrant or award Common | +5,768 | $45.00 | $260k | 35,313 | Dec 9, 2024 |
| Dec 4, 2024 | David Dong Wang SVP & GM, SMS | DDisposition to issuer Common | -140 | $46.65 | $6,531 | 23,974 | Dec 5, 2024 |
| Nov 19, 2024 | Ginger Zhou SVP and General Manager, Genom | SOpen-market sale Common | -491 | $40.07 | $20k | 27,499 | Nov 21, 2024 |
| Nov 19, 2024 | Olga Pirogova SVP and CHRO | SOpen-market sale Common | -548 | $40.07 | $22k | 19,373 | Nov 21, 2024 |
| Nov 19, 2024 | Violetta Hughes VP, Chief Accounting Officer | SOpen-market sale Common | -163 | $40.07 | $6,531 | 9,920 | Nov 21, 2024 |
| Nov 19, 2024 | David Dong Wang SVP & GM, SMS | SOpen-market sale Common | -348 | $40.07 | $14k | 24,114 | Nov 21, 2024 |
| Nov 19, 2024 | Herman Cueto EVP, Chief Financial Officer | SOpen-market sale Common | -712 | $40.07 | $29k | 23,892 | Nov 21, 2024 |
| Nov 19, 2024 | Jason Joseph SVP, General Counsel, Secy. | SOpen-market sale Common | -1,139 | $40.07 | $46k | 112,564 | Nov 21, 2024 |
| Nov 15, 2024 | David Dong Wang SVP & GM, SMS | AGrant or award Common | +8,651 | $41.51 | $359k | 24,462 | Nov 19, 2024 |
| Nov 15, 2024 | Olga Pirogova SVP and CHRO | AGrant or award Common | +10,381 | $41.51 | $431k | 19,921 | Nov 19, 2024 |
| Nov 15, 2024 | John Marotta President and CEO | AGrant or award Common | +83,622 | $41.51 | $3.5M | 86,895 | Nov 19, 2024 |
| Nov 15, 2024 | Jason Joseph SVP, General Counsel, Secy. | AGrant or award Common | +13,841 | $41.51 | $575k | 113,703 | Nov 19, 2024 |
| Nov 15, 2024 | Violetta Hughes VP, Chief Accounting Officer | AGrant or award Common | +6,921 | $41.51 | $287k | 10,083 | Nov 19, 2024 |
| Nov 15, 2024 | Ginger Zhou SVP and General Manager, Genom | AGrant or award Common | +8,651 | $41.51 | $359k | 27,990 | Nov 19, 2024 |
| Nov 18, 2024 | Didier Hirsch director | POpen-market purchase Common | +1,000 | $39.50 | $40k | 3,465 | Nov 19, 2024 |
| Nov 18, 2024 | William L Cornog director | POpen-market purchase Commonindirect: See footnote | +12,500 | $39.60 | $495k | 14,755 | Nov 19, 2024 |
| Nov 19, 2024 | Martin D Madaus Interim CEO | POpen-market purchase Common | +4,940 | $40.77 | $201k | 7,405 | Nov 19, 2024 |
| Nov 18, 2024 | John Marotta President and CEO | POpen-market purchase Common | +12,717 | $39.48 | $502k | 99,612 | Nov 19, 2024 |
| Nov 19, 2024 | John Marotta President and CEO | POpen-market purchase Common | +1,250 | $40.67 | $51k | 100,862 | Nov 19, 2024 |
| Nov 6, 2024 | Alan J Malus director | DDisposition to issuer Common | +995 | $46.52 | $46k | 995 | Nov 14, 2024 |
| Nov 6, 2024 | William L Cornog director | DDisposition to issuer Common | -995 | $46.52 | $46k | 2,255 | Nov 8, 2024 |
| Nov 6, 2024 | Quentin Koffey director | AGrant or award Common Stock | +995 | $0.00 | $0 | 995 | Nov 8, 2024 |
| Oct 17, 2024 | Herman Cueto EVP, Chief Financial Officer | SOpen-market sale Common | -1,595 | $43.68 | $70k | 24,604 | Oct 21, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Erik J. BelloVP Chief Accounting Officer
- Frank Casaldirector
- William L Cornogdirector
- Herman CuetoEVP, Chief Financial Officer
- Robyn C Davisdirector
- Dipal Doshidirector, ceo, officer
- Didier Hirschdirector
- Violetta HughesVP, Chief Accounting Officer
- Jason JosephSVP, General Counsel, Secy.
- Quentin Koffeydirector
- Lawrence Y. LinEVP, CFO and Treasurer
- William E. Martin IIIPresident Multiomics
- Martin D MadausInterim CEO
- Alan J Malusdirector
- John MarottaPresident and CEO
- Erica McLaughlincfo, officer, director
- Tina Susan Novadirector
- Olga PirogovaSVP and CHRO
- Ephraim StarrSVP, Gen Counsel & Secretary
- David Dong WangSVP & GM, SMS
- Ginger ZhouSVP and GM, Multiomics
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.